Editorial Board Member - JCS
Suling Liu
ProfessorSchool of Life Sciences
University of Science & Technology
China
RESEARCH INTERESTS:
- Identifying different states of breast stem cells to develop the novel combination therapies targeting different breast cancer stem cells.
- Investigating the combination therapy of PARPi and 17-AAG to target cancer stem cells in Triple-negative breast cancers.
- Studying the effects of microRNAs on breast cancer stem cell self-renewal and differentiation, and develop some miRNA-based therapies with nanotechnology.
- Studying the tumor microenvironment in regulating breast cancer stem cells
Other Editorial Board Members - JCS
Sanjay D. Deshmukh
Professor
Department of Pathology
Smt. Kashibai Navale Medical College and General Hospital
India
Department of Pathology
Smt. Kashibai Navale Medical College and General Hospital
India
Michael Gibson
Associate Professor
Department of Medicine
Case Western Reserve University
United States
Department of Medicine
Case Western Reserve University
United States
Gary Lee Francis
Professor
Division of Endocrinology and Metabolism
Medical College of Virginia
United States
Division of Endocrinology and Metabolism
Medical College of Virginia
United States
XIAOYANG QI
Associate Director
Division of Hematology-Oncology
Department of Internal Medicine
University of Cincinnati
United States
Division of Hematology-Oncology
Department of Internal Medicine
University of Cincinnati
United States
Rodrigo Fernandez Valdivia
Assistant Professor
Department of Pathology
Wayne State University School of Medicine
United States
Department of Pathology
Wayne State University School of Medicine
United States
Markus Müschen
Professor
Department of Laboratory Medicine
University of California, San Francisco
United States
Department of Laboratory Medicine
University of California, San Francisco
United States
Rajkumar Vajpeyi
Assistant Professor
Laboratory Medicine and Pathobiology
University of Toronto
Canada
Laboratory Medicine and Pathobiology
University of Toronto
Canada
